Based on 8 Billion Shares and Option plus expected capital raising some times in June or July, If I compare with CUX, their exploration results so on, DMN is definitely overpriced.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025